Yeast in Gut Shows Promise for Targeted Drug Delivery

New study identifies key genes and metabolic processes that could enable more efficient probiotic-based drug delivery

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

A new study from researchers at North Carolina State University offers a deeper understanding of how the probiotic yeast Saccharomyces boulardii behaves within the gut, potentially paving the way for more effective, targeted drug delivery systems. The researchers identified key genes and metabolic processes within the yeast that could be leveraged to create engineered probiotic strains capable of producing therapeutic drugs with greater efficiency and precision.

Why it matters

This research builds on previous studies demonstrating the potential of using engineered probiotic yeasts as 'live biotherapeutics' to deliver drugs and combat conditions like inflammatory bowel disease and gastrointestinal cancers. By gaining a better understanding of the yeast's genetic and metabolic activity in the gut environment, researchers can now more effectively design and optimize yeast-based drug delivery platforms.

The details

The researchers focused on the Saccharomyces boulardii (Sb) yeast species, which is already used as a probiotic. They introduced an unmodified Sb strain into laboratory mice bred to be 'germ-free', allowing for a clearer analysis of the yeast's activity. By collecting fecal and intestinal samples, the researchers used a combination of analytical techniques to measure RNA production within the yeast cells as they moved through the digestive system. This revealed which Sb yeast genes are most responsive to the gut environment, providing 'on-switches' that could be targeted to ensure the yeast produces therapeutic molecules when desired. The study also found that genes associated with potentially harmful yeast behaviors were not activated in the gut.

  • The research was published in the journal BMC Genomics in February 2026.

The players

Nathan Crook

Associate professor of chemical and biomolecular engineering at North Carolina State University and the study's corresponding author.

Juliane Nguyen

Researcher at the University of North Carolina Chapel Hill who published a 2024 study demonstrating the successful engineering of Saccharomyces boulardii to deliver drugs and reduce inflammation in mouse models of inflammatory bowel disease.

Janelle Arthur

Researcher at the University of North Carolina Chapel Hill who published a 2024 study demonstrating the successful engineering of Saccharomyces boulardii to deliver drugs and reduce inflammation in mouse models of inflammatory bowel disease.

Got photos? Submit your photos here. ›

What they’re saying

“Yeast is promising as a drug-delivery platform.”

— Nathan Crook, Associate professor of chemical and biomolecular engineering

“We knew yeasts could do this, but we didn't know how. Which genes are turned off or on? What is the yeast eating? Is the yeast producing any other molecules that might be harmful?”

— Nathan Crook, Associate professor of chemical and biomolecular engineering

“One of the key findings is that we've identified which genes in the Sb yeast are much more likely to be activated when in the gut as opposed to other environments. That tells us which sections of DNA are most responsive to the gut environment. And that is useful because People can then target these 'promoter' sections of DNA as on-switches that tell the yeast cell when to start producing therapeutic molecules.”

— Nathan Crook, Associate professor of chemical and biomolecular engineering

What’s next

The researchers have filed patent applications and invention disclosures related to the engineering of probiotic yeast based on this study.

The takeaway

This research provides a crucial foundation for ongoing efforts to leverage engineered probiotic yeasts as 'live biotherapeutics' capable of delivering targeted drugs and treatments for conditions like inflammatory bowel disease and gastrointestinal cancers.